Methods and compositions for inhibiting the interaction of menin with MLL proteins

US10077271B2 · kind B2 · utility

Assignees

• Kura Oncology, Inc. · US
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

• Jolanta Grembecka · Ann Arbor, US
• Tomasz Cierpicki · Ann Arbor, US
• Dmitry Borkin · Ann Arbor, US
• Jonathan Pollock · Ann Arbor, US
• Liansheng Li · San Diego, US
• Tao Wu · Carlsbad, US
• Jun Feng · San Diego, US
• Pingda Ren · San Diego, US
• Yi Liu · San Diego, US
• Szymon Klossowski · Ann Arbor, US

Key dates

• Filing date: Dec 1, 2017
• Grant date: Sep 18, 2018
• Expiry date: Dec 1, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.